ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 109 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2016. The put-call ratio across all filers is 0.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $116,070 | -65.9% | 73,000 | +33.7% | 0.00% | – |
| Q4 2022 | $340,158 | +18.1% | 54,600 | +27.1% | 0.00% | – |
| Q3 2022 | $288,000 | +23.1% | 42,953 | +16.7% | 0.00% | – |
| Q2 2022 | $234,000 | +78.6% | 36,800 | +30.0% | 0.00% | – |
| Q1 2022 | $131,000 | -7.7% | 28,300 | 0.0% | 0.00% | – |
| Q4 2021 | $142,000 | -58.7% | 28,300 | -0.9% | 0.00% | – |
| Q3 2021 | $344,000 | -43.0% | 28,570 | 0.0% | 0.00% | – |
| Q2 2021 | $604,000 | -9.4% | 28,570 | +20.2% | 0.00% | – |
| Q1 2021 | $667,000 | -14.7% | 23,770 | -21.0% | 0.00% | – |
| Q4 2020 | $782,000 | -30.1% | 30,070 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $1,118,000 | -39.9% | 30,070 | -17.1% | 0.00% | 0.0% |
| Q2 2020 | $1,861,000 | +78.9% | 36,270 | +10.0% | 0.00% | 0.0% |
| Q1 2020 | $1,040,000 | -47.1% | 32,970 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $1,966,000 | -14.1% | 32,970 | -47.2% | 0.00% | 0.0% |
| Q3 2019 | $2,290,000 | -21.2% | 62,464 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $2,906,000 | +162.5% | 62,464 | +126.6% | 0.00% | +100.0% |
| Q1 2019 | $1,107,000 | -12.7% | 27,570 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $1,268,000 | -18.0% | 27,570 | -20.9% | 0.00% | 0.0% |
| Q3 2018 | $1,547,000 | +13.2% | 34,870 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,367,000 | -37.6% | 34,870 | +15.2% | 0.00% | -50.0% |
| Q1 2018 | $2,189,000 | -4.9% | 30,270 | -13.4% | 0.00% | 0.0% |
| Q4 2017 | $2,302,000 | +84.0% | 34,970 | +40.0% | 0.00% | +100.0% |
| Q3 2017 | $1,251,000 | -10.1% | 24,970 | -17.0% | 0.00% | 0.0% |
| Q2 2017 | $1,392,000 | +38.0% | 30,070 | +5.3% | 0.00% | 0.0% |
| Q1 2017 | $1,009,000 | +157.4% | 28,570 | -8.6% | 0.00% | – |
| Q4 2016 | $392,000 | -9.5% | 31,270 | 0.0% | 0.00% | – |
| Q3 2016 | $433,000 | +40.1% | 31,270 | 0.0% | 0.00% | – |
| Q2 2016 | $309,000 | -18.3% | 31,270 | +39.8% | 0.00% | – |
| Q1 2016 | $378,000 | -24.1% | 22,370 | 0.0% | 0.00% | – |
| Q4 2015 | $498,000 | -11.2% | 22,370 | -5.9% | 0.00% | – |
| Q3 2015 | $561,000 | -87.5% | 23,770 | -56.5% | 0.00% | -100.0% |
| Q2 2015 | $4,471,000 | +223.3% | 54,690 | +266.1% | 0.00% | +300.0% |
| Q1 2015 | $1,383,000 | -26.0% | 14,940 | -67.7% | 0.00% | -50.0% |
| Q4 2014 | $1,870,000 | +33.9% | 46,230 | -19.1% | 0.00% | +100.0% |
| Q3 2014 | $1,397,000 | +53.5% | 57,130 | -0.5% | 0.00% | 0.0% |
| Q2 2014 | $910,000 | +5.7% | 57,430 | +0.9% | 0.00% | 0.0% |
| Q1 2014 | $861,000 | +10.1% | 56,928 | 0.0% | 0.00% | 0.0% |
| Q4 2013 | $782,000 | +39000.0% | 56,928 | +57989.8% | 0.00% | – |
| Q3 2013 | $2,000 | – | 98 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |